Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02806713 · ClinicalTrials.gov registry record · Phase 3
The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)
A Phase 3 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT02806713: Completed Phase 3 study, sponsored by University of Massachusetts, Worcester.
NCT02806713 is a Phase 3 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 92 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02806713, a Phase 3 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
Randomized clinical trial using phenazopyridine to decrease voiding dysfunction after a retropubic midurethral sling operation.
Primary Outcome
Number of participants with a failed postoperative voiding trial. A failed voiding trial is defined as not voiding all urine in 20 minutes or voiding less than 1/3 of total volume (voided volume + post void residual). Patients will undergo voiding trial at same day surgery per the following protocol. Participants who do not pass the voiding trial the same day of their surgical procedure return to the clinic in 3 days to repeat it, following the same protocol described above.
Interventions
- DRUG Phenazopyridine
- OTHER no Phenazopyridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-08 |
| Phase | Phase 3 |
What the finished NCT02806713 record still lists
NCT02806713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Phenazopyridine is the first listed.
NCT02806713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02806713 about?
NCT02806713 is a clinical study titled "The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)". Randomized clinical trial using phenazopyridine to decrease voiding dysfunction after a retropubic midurethral sling operation.
What is the current status of trial NCT02806713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2016-02. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02806713?
The interventions under investigation include: Phenazopyridine (DRUG), no Phenazopyridine (OTHER).
Who is sponsoring clinical trial NCT02806713?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02806713's enrollment target sits among peer trials
92 1723rd of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia